Drugs in MeSH Category Sweetening Agents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%	mannitol	INJECTABLE;INJECTION	016080-005	Approved Prior to Jan 1, 1982		DISCN	No	No
Hospira	MANNITOL 20%	mannitol	INJECTABLE;INJECTION	016269-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Pharmaxis Europe	BRONCHITOL	mannitol	POWDER;INHALATION	202049-001	Oct 30, 2020		RX	Yes	Yes
Baxter Hlthcare	OSMITROL 15% IN WATER	mannitol	INJECTABLE;INJECTION	013684-004	Approved Prior to Jan 1, 1982	AP	RX	No	No
B Braun	MANNITOL 15% IN PLASTIC CONTAINER	mannitol	INJECTABLE;INJECTION	020006-003	Jul 26, 1993	AP	RX	No	No
B Braun	MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER	mannitol	INJECTABLE;INJECTION	016080-006	Approved Prior to Jan 1, 1982		DISCN	No	No

Last updated: July 17, 2026

Market dynamics and patent landscape for sweetening agents (NLM MeSH)

Sweetening agents sit at the intersection of consumer-safety regulation and IP-driven market control. Patent position is typically concentrated around: (1) high-intensity sweeteners (HIS) with proprietary compositions and manufacturing controls, (2) taste-masking and formulation technologies for sweetener blends, and (3) novel sweetener molecules or analogs with improved stability, onset, and caloric or metabolic profiles. Market dynamics are shaped by persistent demand for low- and no-calorie products, price and supply constraints in key upstream inputs, and ongoing regulatory scrutiny tied to acceptable daily intake (ADI), labeling, and stability in foods.

For a patent analyst, the practical scope is narrow even though MeSH “Sweetening Agents” spans many substances: the IP that materially affects competition is usually in FDA-regulated food additive contexts or in drug-like sweetener applications (for example, oral dosage palatability, pediatric formulations, and therapeutic sweetener uses). In contrast, basic sweetener molecules with early priority dates often face generic or “equivalent ingredient” competition unless patents persist on formulations, processes, or specific use patterns.

---

Which sweetening agents dominate the market and why do patents matter?

Sweetening-ingredient competition is driven by (a) functional performance in specific food matrices, (b) regulatory acceptance and labeling pathways, and (c) supply chain resiliency for the underlying chemicals.

High-intensity sweeteners (HIS) with patent-relevant ecosystems

1. Steviol glycosides (stevia extracts)
2. Aspartame
3. Sucralose
4. Saccharin and sodium cyclamate (depending on region)
5. Acesulfame potassium (acesulfame K)
6. Neotame
7. Advantame
8. Thaumatin and related natural proteins (and engineered variants)
9. Monellin, glycosylated variants, and other sweet proteins
10. Allulose (rare sugar; often positioned as metabolic sweetener)

Patent leverage points that actually move outcomes

• Formulation patents for “sweetener systems” (blend ratios, buffering, encapsulation, crystal engineering, flavor masking).
• Manufacturing process patents that improve yield, reduce impurities, or stabilize isomers.
• Stability and sensory patents (thermal stability, pH stability, aftertaste suppression).
• Regulatory-use claims tied to specific food uses or dosage forms where a sweetener is part of a regulated product system.
• Method-of-use patents in therapeutic or pharmaceutical palatability contexts (oral liquids, chewables, pediatric syrups).

---

What patents protect stevia, aspartame, sucralose, and other major sweeteners?

Patent coverage for classic HIS is bifurcated: molecule-level claims typically originate early and have largely expired or are near expiry, while “evergreening” shifts toward formulation and process.

Steviol glycosides

Key IP patterns

• Extraction/purification and fractionation strategies that standardize specific steviol glycosides (for example, rebaudioside profiles).
• Encapsulation and taste-masking systems that address bitterness and lingering aftertaste.
• Blend patents pairing stevia with bulking agents and flavor enhancers.

Who tends to hold relevant estates

• Large natural-extract ingredient companies and ingredient brands built on standardized steviol glycosides, plus flavor houses and encapsulation technology providers.

Aspartame

Key IP patterns

• Manufacturing processes controlling diketopiperazine (DKP) impurities, stability controls, and crystallization methods.
• Composition patents for blends to reduce aftertaste, improve sweetness profile, and extend shelf life.

Competitive reality

• Aspartame has long-standing market presence. Patent-driven differentiation is more about impurity control and formulation than about the molecule itself.

Sucralose

Key IP patterns

• Process controls for isomer purity and stability, plus granular particle engineering that improves dispersibility.
• Formulation patents for beverage systems and dry mixes.

Acesulfame K, saccharin, cyclamate

Key IP patterns

• Often less about molecule novelty and more about specific uses, blend systems, and regulatory-compliant manufacturing.

Sweet proteins (thaumatin, monellin)

Key IP patterns

• Protein engineering claims, gene construct claims, expression system/process claims, and formulation stabilization (thermal and pH stability).
• Proprietary recovery and purification and shelf-stable composition technologies.

---

When do sweetening-agent patents lose exclusivity?

There is no single expiry date across MeSH “Sweetening Agents” because the category spans multiple generations of ingredients.

Practical timing framework

1. Molecule patents: typically expired or close to expiration for many legacy HIS (aspartame, saccharin, sucralose-era innovations). Competitive entry often depends on regulatory and manufacturing quality rather than on hard molecule exclusivity.
2. Process and purification patents: persist longer because improvements are iterative and region-specific.
3. Formulation and delivery technology patents: can extend effective exclusivity by locking in specific product performance claims.

What this means for “generic entry”

For sweeteners, “generic” often means functional equivalents and approved ingredient substitutes rather than a typical FDA drug generic. If the market is food/additive-driven, exclusivity can be set by:

• ingredient specifications,
• approval status by region,
• and patent claims around proprietary compositions and processes.

---

How many formulation and taste-masking patents cover sweeteners, and which are most defensible?

Defensibility clusters around:

• Objective performance parameters (aftertaste metrics, sweetness onset curves, stability in beverage pH ranges).
• Composition structure tied to functional outcomes (blend ratios, encapsulation particle size ranges, coating materials).
• Process claims that narrow design-around space (impurity profiles, specific purification steps).

Patent filings in this space frequently include:

• sweetener blend compositions (HIS + bulking agents + flavor enhancers),
• encapsulated sweetener delivery systems,
• and buffering compositions that reduce bitterness or metallic notes.

---

Which companies dominate patent estates in sweetening agents?

Sweetener IP is concentrated among:

• global ingredient manufacturers,
• flavor houses and co-manufacturers with formulation platforms,
• and specialty bioprocessing companies for sweet proteins.

Market leadership tends to track:

• control of downstream application know-how (beverage vs confection vs baked goods),
• and the ability to supply consistent high-purity ingredients at scale.

---

What is the Orange Book status of sweetening agents?

Sweetening agents are generally not prescribed in the FDA “Orange Book” framework unless they are part of an approved drug product with active pharmaceutical ingredient (API) status or an approved drug application’s listed component. Most sweeteners function as food additives or dietary ingredients, so the typical exclusivity reference point is not Orange Book.

For patent defense and entry analysis, the practical equivalents are:

• patent listing systems tied to food ingredient approvals (region-dependent),
• and patent prosecution records in relevant jurisdictions,
• plus litigation histories in ingredient markets.

---

What patent litigation affects sweeteners and sweetener blends?

Sweetener IP disputes typically arise in one of three lanes:

1. Ingredient process and purification (impurity control and manufacturing methods).
2. Taste-masking/formulation compositions (blend ratios, encapsulation).
3. Sweet protein engineering and production (sequence claims, construct/process claims, and stabilization formulation).

Where litigation exists, settlements often:

• constrain specific blend compositions,
• require design-around of manufacturing steps,
• or limit the use of certain stabilized formulations in certain application channels.

---

Which regulatory pathways control sweeteners and how do they interact with IP?

Sweetening agents usually face regulatory frameworks for:

• Food additive approval or “generally recognized” pathways (region-dependent).
• Dietary supplement rules if positioned as such.
• Labeling and ADIs that can constrain marketing claims even if IP expires.

IP and regulatory status interact in practice:

• even after patent expiry, entry requires a regulatory-compatible ingredient specification;
• process patents can still block supply if a manufacturer must use a non-infringing manufacturing route.

---

How does sweetener patent strength compare with competing substitutes (e.g., allulose vs stevia vs sucralose)?

Patent strength in this category is more about application capture than molecule monopoly.

Comparative pattern

• Allulose (rare sugar): patent portfolios can emphasize metabolic effects positioning, purification/process, and specific end-use compositions.
• Stevia: patents emphasize standardized steviol glycoside fractions, purification, encapsulation, and blend systems.
• Sucralose/aspartame: patents more often relate to manufacturing control, impurity management, and blend compositions that mitigate aftertaste or improve stability.

The strongest “business-critical” estates are usually those that cover:

• proprietary formulation systems used by major beverage brands or confection manufacturers,
• and the production method needed to achieve consistent sensory and stability targets.

---

What generic entry risks exist for sweetening agents?

“Entry risk” has a different shape than in pharmaceuticals.

Core risks to generic/alternative entrants

• Patent coverage of blend formulations: even if the sweetener molecule is free, a specific marketed system may be patented.
• Process and impurity patents: suppliers must avoid infringing manufacturing controls.
• Sweet protein sequence and production claims: engineered proteins can have tight protection around constructs and expression systems.

What decreases risk

• Using functionally similar ingredients that do not fall within composition claim parameters.
• Using alternative encapsulation or manufacturing methods.
• Focusing on application categories not covered by the patented blend system.

---

Which manufacturing/IP barriers block supply of sweeteners at scale?

Barrier types:

• Purification and standardization requirements for stevia fractions or protein sweetness profiles.
• Impurity control for legacy HIS with well-defined specification targets (for example, DKP-related control for aspartame).
• Encapsulation platform IP (coating chemistry, particle size distribution, and stability under storage conditions).

If a supplier must adopt the incumbent’s proprietary process to meet specs, it may face increased non-infringement complexity.

---

Key takeaways

• Sweetening agents are competitive where patents cover formulation performance and manufacturing controls, not where they protect the base molecule alone.
• Market dynamics are driven by functional performance, regulatory acceptance, and supply consistency, with patents used to protect proprietary ingredient systems.
• The most actionable patent estates typically target sweetener blends, taste-masking, encapsulation/delivery, and process impurity profiles.
• “Exclusivity” in this space is often less about Orange Book-style drug exclusivity and more about patent-guarded compositions/process routes plus regulatory-compliant specifications.
• Generic/alternative entry risk persists even after molecule-level patent expiry, especially for patented applications and manufacturing methods.

---

FAQs

1) What patent types most frequently cover sweetener taste-masking and aftertaste reduction?
Composition claims (sweetener blend ratios), encapsulation/delivery systems, and stability-buffering formulations tied to sensory performance.

2) How do manufacturing-process patents create barriers even when sweetener molecules are widely available?
They can protect specific purification steps, impurity targets, and controlled crystallization or fractionation methods required to meet tight ingredient specs.

3) Are sweeteners generally protected under Orange Book listings?
Typically no, unless a sweetener is an API in a specific approved drug product. Most sweeteners are regulated as food/dietary ingredients.

4) What disputes are most common in sweetener patent litigation?
Ingredient process and purification, sweetener blend formulations for specific performance outcomes, and sweet protein engineering/production.

5) What is the fastest path for an alternative supplier to reduce infringement risk?
Design around patented blend ratios/delivery systems and use alternative manufacturing routes that avoid protected process steps and impurity control methods.

---

References

1. U.S. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-07-17).
2. NLM. MeSH Browser. Sweetening Agents. (Accessed 2026-07-17).
3. U.S. FDA. Food Additives and GRAS Notices. (Accessed 2026-07-17).